These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
54 related articles for article (PubMed ID: 160836)
21. Activity of JM9 in advanced ovarian cancer: a phase I-II trial. Bramwell VH; Crowther D; O'Malley S; Swindell R; Johnson R; Cooper EH; Thatcher N; Howell A Cancer Treat Rep; 1985 Apr; 69(4):409-16. PubMed ID: 3995511 [TBL] [Abstract][Full Text] [Related]
22. Phase II trial of topotecan administered as 72-hour continuous infusion in children with refractory solid tumors: a collaborative Pediatric Branch, National Cancer Institute, and Children's Cancer Group Study. Blaney SM; Needle MN; Gillespie A; Sato JK; Reaman GH; Berg SL; Adamson PC; Krailo MD; Bleyer WA; Poplack DG; Balis FM Clin Cancer Res; 1998 Feb; 4(2):357-60. PubMed ID: 9516923 [TBL] [Abstract][Full Text] [Related]
23. Phase I study of tricyclic nucleoside phosphate. Mittelman A; Casper ES; Godwin TA; Cassidy C; Young CW Cancer Treat Rep; 1983 Feb; 67(2):159-62. PubMed ID: 6825123 [TBL] [Abstract][Full Text] [Related]
24. Phase I study of combined pegylated liposomal doxorubicin with protracted daily topotecan for ovarian cancer. Mirchandani D; Hochster H; Hamilton A; Liebes L; Yee H; Curtin JP; Lee S; Sorich J; Dellenbaugh C; Muggia FM Clin Cancer Res; 2005 Aug; 11(16):5912-9. PubMed ID: 16115933 [TBL] [Abstract][Full Text] [Related]
25. Phase I clinical and pharmacokinetic study of taxol. Wiernik PH; Schwartz EL; Strauman JJ; Dutcher JP; Lipton RB; Paietta E Cancer Res; 1987 May; 47(9):2486-93. PubMed ID: 2882837 [TBL] [Abstract][Full Text] [Related]
26. Initial clinical trials of maytansine, an antitumor plant alkaloid. Chabner BA; Levine AS; Johnson BL; Young RC Cancer Treat Rep; 1978 Mar; 62(3):429-33. PubMed ID: 348311 [TBL] [Abstract][Full Text] [Related]
27. Phase II evaluation of amsacrine (m-AMSA) in solid tumors, myeloma, and lymphoma: a University of Arizona and Southwest Oncology Group Study. Ahmann FR; Meyskens FL; Jones SE; Bukowski RM; Saiers JH; Ryan DH; Costanzi J; Vaughn CB; Coltman CA Cancer Treat Rep; 1983; 67(7-8):697-700. PubMed ID: 6688199 [TBL] [Abstract][Full Text] [Related]
28. Phase I trial of high-dose melphalan, high-dose etoposide and autologous bone marrow re-infusion in solid tumors: an Eastern Cooperative Oncology Group (ECOG) study. Lazarus HM; Gray R; Ciobanu N; Winter J; Weiner RS Bone Marrow Transplant; 1994 Sep; 14(3):443-8. PubMed ID: 7994270 [TBL] [Abstract][Full Text] [Related]
29. Preliminary report on a phase I study of ifosfamide and vinorelbine (navelbine) in advanced non-small cell lung cancer. Masters GA; Hoffman PC; Drinkard LC; Watson S; Samuels BL; Golomb HM; Vokes EE Semin Oncol; 1996 Apr; 23(2 Suppl 5):11-8. PubMed ID: 8610230 [TBL] [Abstract][Full Text] [Related]
30. Doxorubicin, ifosfamide, and dacarbazine (AID) with mesna uroprotection for advanced untreated sarcoma: a phase I study. Elias AD; Antman KH Cancer Treat Rep; 1986 Jul; 70(7):827-33. PubMed ID: 3087617 [TBL] [Abstract][Full Text] [Related]
31. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Atkins MB; Robertson MJ; Gordon M; Lotze MT; DeCoste M; DuBois JS; Ritz J; Sandler AB; Edington HD; Garzone PD; Mier JW; Canning CM; Battiato L; Tahara H; Sherman ML Clin Cancer Res; 1997 Mar; 3(3):409-17. PubMed ID: 9815699 [TBL] [Abstract][Full Text] [Related]
32. Phase I clinical study with pharmacokinetic analysis of 2-beta-D-ribofuranosylthiazole-4-carboxamide (NSC 286193) administered as a five-day infusion. Trump DL; Tutsch KD; Koeller JM; Tormey DC Cancer Res; 1985 Jun; 45(6):2853-8. PubMed ID: 3986812 [TBL] [Abstract][Full Text] [Related]
33. Treatment of patients with advanced malignant lymphoma using gallium nitrate administered as a seven-day continuous infusion. Warrell RP; Coonley CJ; Straus DJ; Young CW Cancer; 1983 Jun; 51(11):1982-7. PubMed ID: 6839291 [TBL] [Abstract][Full Text] [Related]
34. A phase I study of chlorozotocin (NSC 178248). Kovach JS; Moertel CG; Schutt AJ; Frytak S; O'Connell MJ; Rubin J; Ingle JN Cancer; 1979 Jun; 43(6):2189-96. PubMed ID: 156580 [TBL] [Abstract][Full Text] [Related]
35. Streptozotocin therapy in 22 cancer patients. DuPriest RW; Huntington MC; Massey WH; Weiss AJ; Wilson WL; Fletcher WS Cancer; 1975 Feb; 35(2):358-67. PubMed ID: 122912 [TBL] [Abstract][Full Text] [Related]
36. Clinical evaluation of Asaley. Bodey GP; Gottlieb JA; Burgess MA; Alexanian R Med Pediatr Oncol; 1977; 3(4):365-71. PubMed ID: 927333 [TBL] [Abstract][Full Text] [Related]
37. Phase I study of 5-azacytidine (NSC-102816) using 24-hour continuous infusion for 5 days. Lomen PL; Baker LH; Neil GL; Samson MK Cancer Chemother Rep; 1975; 59(6):1123-6. PubMed ID: 56988 [TBL] [Abstract][Full Text] [Related]
38. Phase I evaluation of anguidine (diacetoxyscirpenol, NSC-141537). Goodwin W; Haas CD; Fabian C; Heller-Bettinger I; Hoogstraten B Cancer; 1978 Jul; 42(1):23-6. PubMed ID: 667795 [TBL] [Abstract][Full Text] [Related]
39. Streptozotocin in the treatment of cancer: phase II study. Strolinsky DC; Sadoff L; Braunwald J; Bateman JR Cancer; 1972 Jul; 30(1):61-7. PubMed ID: 4261143 [No Abstract] [Full Text] [Related]